| Title |
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic TherapyPreclinical Optimization of Anti-BCMA/CD3 Therapy in Myeloma
|
|---|---|
| Published in |
Blood Cancer Discovery, May 2021
|
| DOI | 10.1158/2643-3230.bcd-21-0038 |
| Pubmed ID | |
| Authors |
Erin W. Meermeier, Seth J. Welsh, Meaghen E. Sharik, Megan T. Du, Victoria M. Garbitt, Daniel L. Riggs, Chang-Xin Shi, Caleb K. Stein, Marco Bergsagel, Bryant Chau, Matthew L. Wheeler, Natalie Bezman, Feng Wang, Pavel Strop, P. Leif Bergsagel, Marta Chesi |
X Demographics
The data shown below were collected from the profiles of 46 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 23 | 50% |
| Thailand | 2 | 4% |
| Russia | 1 | 2% |
| Germany | 1 | 2% |
| Mexico | 1 | 2% |
| Kenya | 1 | 2% |
| Unknown | 17 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 25 | 54% |
| Scientists | 15 | 33% |
| Practitioners (doctors, other healthcare professionals) | 3 | 7% |
| Science communicators (journalists, bloggers, editors) | 3 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 10% |
| Student > Bachelor | 4 | 10% |
| Student > Master | 4 | 10% |
| Researcher | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 5 | 13% |
| Unknown | 14 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 21% |
| Immunology and Microbiology | 7 | 18% |
| Biochemistry, Genetics and Molecular Biology | 4 | 10% |
| Unspecified | 3 | 8% |
| Arts and Humanities | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 15 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 58. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2024.
All research outputs
#738,604
of 25,432,721 outputs
Outputs from Blood Cancer Discovery
#33
of 211 outputs
Outputs of similar age
#20,536
of 454,000 outputs
Outputs of similar age from Blood Cancer Discovery
#4
of 20 outputs
Altmetric has tracked 25,432,721 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 211 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,000 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.